Zenotech Laboratories Ltd (ZENOTECH) — shareholding pattern, promoter holding, financials and share price
About Zenotech Laboratories Ltd (ZENOTECH)
Zenotech Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ZENOTECH and on the BSE under scrip code 532039. Its ISIN is INE486F01012.
Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products [1]
Zenotech Laboratories Limited specializes in manufacturing pharmaceutical specialty generic injectables. It serves therapeutic areas such as oncology and anesthesiology, providing critical care solutions.
The company has undergone multiple mergers, significantly enhancing its product portfolio, particularly in oncology, with 15 generic chemical oncology products launched in India.
Listed peers in Pharmaceuticals: Everest Organics Ltd, BDH Industries Ltd, Astonea Labs Ltd, Lyka Labs Ltd, Aarey Drugs & Pharmaceuticals Ltd, Gennex Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹44.5 a share on 10 Jul 2026, Zenotech Laboratories Ltd (ZENOTECH) was valued at a price-to-earnings ratio of -254.34x against an industry P/E of 36.41x and a price-to-book of 2.83x on a book value of ₹15.75 per share as of Mar 2025. Solomo computes return on equity of -1.11% and return on capital employed of 4.36% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -254.34x
- Industry P/E
- 36.41x
- P/B
- 2.83x
- EPS (TTM)
- ₹-0.18
- Book value / share
- ₹15.75
- ROE
- -1.11%
- ROCE
- 4.36%
- ROA
- -0.96%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 28.56%
- 52-week range
- ₹33.55 – ₹64
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2010In the year ended Mar 2010, Zenotech Laboratories Ltd (ZENOTECH) reported revenue of ₹7 crore, net profit of ₹-13 crore and earnings per share of ₹-2.05. That compares with revenue of ₹6 crore and net profit of ₹-18 crore in Mar 2009. Figures are consolidated, as filed with the exchanges.
In the quarter ended Sep 2006, revenue was ₹5.27 crore and net profit ₹0.73 crore (consolidated).
| Metric | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 12 | 13 | 8 | 6 | 7 |
| Net profit (₹ cr) | -4 | 2 | -16 | -18 | -13 |
| EPS (₹) | - | 0.32 | -2.64 | -2.88 | -2.05 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 39.25% | 10.59% | 5.59% | 9.14% |
| Profit growth | - | -12.23% | -36.74% | 28.74% |
| Stock price CAGR | 1% | -1% | -5% | -22% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 68.84% of Zenotech Laboratories Ltd (ZENOTECH) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0.01%. Market capitalisation was ₹272 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: PADMASREE CHIGURUPATI 5.52%, PAT FINANCIAL CONSULTANTS PRIVATE LIMITED 3.98%, DR. JAYARAM CHIGURUPATI 3.33%, MINAL BHARAT PATEL 1.72%, ZENOTECH LLC 1.14%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 68.84% | - | - | 0.01% | 31.16% |
| Mar 2026 | 68.84% | - | - | 0.01% | 31.16% |
| Dec 2025 | 68.84% | - | - | 0.01% | 31.16% |
| Sep 2025 | 68.84% | - | - | 0.01% | 31.16% |
| Jun 2025 | 68.84% | - | - | 0.01% | 31.16% |
| Mar 2025 | 68.84% | - | - | 0.01% | 31.16% |
| Dec 2024 | 68.84% | - | - | 0.01% | 31.16% |
| Sep 2024 | 68.84% | - | - | 0.01% | 31.16% |